• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy to market USFDA approved drug GLIADEL® for treatment of brain tumor in India

      Posted AtEquitybulls.com

      Gurgaon (Haryana), India, December 3, 2008: Ranbaxy Laboratories Limited (Ranbaxy) today announced that the Company has received import permission for marketing the US FDA approved product GLIADEL® (polifeprosan 20 with carmustine implant) Wafer for the treatment of newly diagnosed high-grade malignant gliomas & recurrent glioblastoma multiforme. Ranbaxy has signed an exclusive licensing agreement with BioPro Pharmaceutical, Inc., (BioPro) USA to promote and market Gliadel® Wafer in India.

      Commenting on the development, Mr. Sanjeev I. Dani, Senior Vice President & Regional Director, Asia & CIS, Ranbaxy said, "We are pleased to bring this lifesaving, high technology product to Indian patients. We are working with BioPro to create a productive relationship by complementing each other's strengths. The licensing agreement, and subsequent launch approval, should enable Ranbaxy to further strengthen its position in the Oncology Segment."

      "We are pleased with the professional and rapid processing of our regulatory application of Gliadel® by the Drug Controller General India's Office," reported Peter Huang, Chairman and CEO of BioPro. "We have an excellent product in Gliadel® and excellent partners in Eisai Inc. and Ranbaxy India. Now, so many brain cancer patients in India will have access to an excellent therapy option."

      Gliadel® Wafer is indicated in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. It is also indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. Gliadel® is the only FDA-approved chemotherapeutic implant for use during surgical resection, providing localized delivery of chemotherapy directly into the cavity created when a brain tumor is removed during surgery.

      Gliadel® is an off-white to pale yellow, roughly dime-sized wafer made up of a biocompatible polymer that contains the chemotherapeutic drug, carmustine (BCNU). After a neurosurgeon removes a high-grade malignant glioma, up to eight wafers are implanted along the walls and floor of the cavity where the tumor was previously located. Once implanted, Gliadel® slowly dissolves, releasing high concentrations of BCNU into the tumor site, which minimizes drug exposure to other areas of the body.

      The product is manufactured by MGI Pharma and BioPro retains the marketing rights in some Asian countries including China, Hong Kong, Taiwan, Korea, Singapore, Indonesia, the Philippines, Malaysia, Thailand, and India. Gliadel® is approved in a number of countries globally including USA, many countries of Europe, Australia, Canada, South Africa, Israel, Korea, Taiwan, Hong Kong, Singapore, Malaysia and Thailand.

      Though there is very limited data available on the incidence of brain tumors in India, according to unofficial sources, the estimated prevalence of CNS tumors in India is 2-5 new cases per 100000 per year. Another source estimates the total number of cases to be around 21,000 per year. Glioblastoma multiforme constitutes about 60-65% of these primary brain tumors.

      BioPro Pharmaceutical is an oncology specialty biopharmaceutical company focused on the commercialization of products in the Pan Asian pharmaceutical markets. BioPro Pharmaceutical has subsidiary operations in greater China, including Beijing, Hong Kong and Taipei, as well as in Korea and works closely with Distributors in Southeast Asia. The company's expertise is in providing creative pharmaceutical solutions to US and European companies, simultaneously addressing the pharmaceutical needs of the Asia region. BioPro Pharmaceutical combines its expertise in the development and commercialization of innovative drug therapies with many years successful experience in the promotion, sales and marketing of pharmaceutical products in Asia.

      December 16, 2008


       

      Share this Article!

    Back to top^